[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342190-105":59,"doc-detail-342190-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","aberrant-fragmentomic-features-of-circulating-cell-free-mitochondrial-dna-as-novel-biomarkers-for-multi-cancer-detection","Aberrant fragmentomic features of circulating cell-free mitochondrial DNA as novel biomarkers for multi-cancer detection","","Fragmentomic features of circulating cell-free mitochondrial DNA (ccf-mtDNA), including fragmentation profile, 5' end base preference, and motif diversity, remain insufficiently understood. Sequencing data from 1607 plasma samples were generated using capture-based next-generation sequencing to characterize ccf-mtDNA fragmentomics. The study showed that ccf-mtDNA fragmentomic patterns differ markedly from those of circulating cell-free nuclear DNA, with region-specific features linked to mitochondrial DNA protein binding, base composition, and structure. Comparing to non-cancer controls, six cancer patient groups displayed aberrant fragmentomic signatures, enabling multi-cancer detection models with AUC values above 0.9322 and tissue-of-origin accuracy near 89.24% in validation cohorts.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/aberrant-fragmentomic-features-of-circulating-cell-free-mitochondrial-dna-as-novel-biomarkers-for-multi-cancer-detection/342190/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/aberrant-fragmentomic-features-of-circulating-cell-free-mitochondrial-dna-as-novel-biomarkers-for-multi-cancer-detection/342190.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What fragmentomic characteristics of ccf-mtDNA were examined in the study?","Question",{"text":112,"@type":113},"The study evaluated fragmentation profile, 5' end base preference, and motif diversity of circulating cell-free mitochondrial DNA.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did ccf-mtDNA fragmentomic features differ from circulating cell-free nuclear DNA?",{"text":117,"@type":113},"ccf-mtDNA fragmentomic features were found to be remarkably different from those of circulating cell-free nuclear DNA, including region-specific patterns.",{"name":119,"@type":110,"acceptedAnswer":120},"How were multi-cancer detection models built and validated?",{"text":121,"@type":113},"Models were constructed using ccf-mtDNA fragmentomic features and evaluated in internal and external validation cohorts, achieving high discrimination with AUC values above 0.9322.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342190,1790194459,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Article  \nAberrant fragmentomic features of circulating cellfree mitochondrial DNA as novel biomarkers for multi-cancer detection  \nYang Liu1,2,4, Fan Peng1,4, Siyuan Wang1,4, Huanmin Jiao1, Miao Dang1, Kaixiang Zhou1, Wenjie Guo 1, Shanshan Guo1, Huanqin Zhang1, Wenjie Song3 & Jinliang Xing 1 ✉  \nAbstract  \nFragmentomic features of circulating cell free mitochondrial DNA (ccf-mtDNA) including fragmentation proﬁle, 5’ end base preference and motif diversity are poorly understood. Here, we generated ccf-mtDNA sequencing data of 1607 plasma samples using capture-based next generation sequencing. We ﬁrstly found that fragmentomic features of ccf-mtDNA were remarkably different from those of circulating cell free nuclear DNA. Furthermore, region-speciﬁc fragmentomic features of ccf-mtDNA were observed, which was associated with protein binding, base composition and special structure of mitochondrial DNA. When comparing to non-cancer controls, six types of cancer patients exhibited aberrant fragmentomic features. Then, cancer detection models were built based on the fragmentomic features. Both internal and external validation cohorts demonstrated the excellent capacity of our model in distinguishing cancer patients from noncancer control, with all area under curve higher than 0.9322 . The overall accuracy of tissue-of-origin was 89.24% and 87.92% for six cancer types in two validation cohort, respectively. Altogether, our study comprehensively describes cancer-speciﬁc fragmentomic features of ccf-mtDNA and provides a proof-of-principle for the ccf-mtDNA fragmentomics-based multi-cancer detection and tissue-of-origin classiﬁcation.  \nKeywords Fragmentomics; Circulating Cell-Free Mitochondrial DNA; Multi-Cancer Detection; Tissue-of-Origin Classiﬁcation; Biomarker Subject Categories Biomarkers; Cancer  \n[https://doi.org/10.1038/s44321-024-00163-6](https://doi.org/10.1038/s44321-024-00163-6)  \nReceived 30 May 2024; Revised 27 September 2024; Accepted 18 October 2024  \nPublished online: 30 October 2024  \nIntroduction  \nThe poor prognosis of numerous patients with cancer are mainly caused by late diagnosis when therapeutic intervention is less effective, especially in developing countries. Unfortunately,  \nclinically proven biomarkers for cancer detection face many challenges, including low sensitivity and speciﬁcity, complicated operations, and data analyses. Liquid biopsy, a powerful complement to traditional methods, has made signiﬁcant breakthroughs in the clinical practices of cancer detection (Nikanjam et al, 2022) . Currently, research is focused on the detection of circulating tumor DNA (ctDNA), including copy number variations, somatic mutations, and methylation (Cescon et al, 2020) . Proﬁling copy number variations and somatic mutations throughout the whole genome has provided feasible methods for cancer detection. However, their sensitivities remain suboptimal, especially in early-stage cancers (Benesova et al, 2013; Tao et al, 2020; Wanget al, 2021) . Furthermore, although a series of methods have been developed, the process of ctDNA methylation analysis remains complex because of the bisulﬁte treatment (Sestakova et al, 2019; Kerachian et al, 2021) . And endonuclease digestion- or afﬁnity enrichment-based methods for ctDNA methylation detecting are prone to sources of bias (Li and Tollefsbol, 2021) .  \nRecently, cell-free DNA (cfDNA) fragmentomic features, which encompass fragment size, end motifs, breakpoint motifs, and nucleosome footprints, have demonstrated the potential of cfDNA fragmentomics in detecting cancers, including lung cancer (Mathios et al, 2021), colorectal cancer (Ma et al, 2021), hepatocellular carcinoma (Jin et al, 2021) . Cristiano et al reported that the genome-wide fragmentation proﬁle of cfDNA differed between patients with cancer and healthy individuals (Cristiano et al, 2019) . Bao et al recently constructed an early detection model for multiple cancers based on cfDNA fragmentomic features obtained ","cbCaimJRkstjyzRn","https://ap.wps.com/l/cbCaimJRkstjyzRn","pdf",2716580,15,"English","# Abstract\n# Introduction","[{\"question\":\"What fragmentomic characteristics of ccf-mtDNA were examined in the study?\",\"answer\":\"The study evaluated fragmentation profile, 5' end base preference, and motif diversity of circulating cell-free mitochondrial DNA.\"},{\"question\":\"How did ccf-mtDNA fragmentomic features differ from circulating cell-free nuclear DNA?\",\"answer\":\"ccf-mtDNA fragmentomic features were found to be remarkably different from those of circulating cell-free nuclear DNA, including region-specific patterns.\"},{\"question\":\"How were multi-cancer detection models built and validated?\",\"answer\":\"Models were constructed using ccf-mtDNA fragmentomic features and evaluated in internal and external validation cohorts, achieving high discrimination with AUC values above 0.9322.\"}]","Aberrant fragmentomic features of circulating cell-free mitochondrial DNA as novel biomarkers for multi-cancer detection | PDF",1790045733,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67ce2937e478665651c783ff130d314a.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5235d7ed2c3fb2445953fa8ecc3ff87.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/74a58390688914e05566c20ad52fae78.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/922645f59e779edd2dc4339f1f8f9c2f.webp",980,1301]